Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Cephalon To Develop Oncology Franchise Following Acquisition Of CTI’s Trisenox

This article was originally published in The Pink Sheet Daily

  • News
  • Lee Kalowski

Executive Summary

Cephalon will build a hematology franchise around the Trisenox acquisition; the company may add its Phase II tyrosine kinase inhibitor (CEP-701) and Salmedix’ lymphoma treatment Treanda when that acqusition closes. CTI is selling Trisenox to reinvest in its late-stage pipeline.

You may also be interested in...



Cephalon Files Treanda For Chronic Lymphocytic Leukemia

Submission represents a milestone for Cephalon’s oncology program, firm says.

Cephalon Files Treanda For Chronic Lymphocytic Leukemia

Submission represents a milestone for Cephalon’s oncology program, firm says.

Cephalon To File Treanda For Two Oncology Indications This Year

Company is on track to file chronic lymphocytic leukemia indication in Q3, followed by non-Hodgkin’s lymphoma in Q4.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

See All
UsernamePublicRestriction

Register

PS062369

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By